Stroke with unknown time of symptom onset: baseline clinical and magnetic resonance imaging data of the first thousand patients in WAKE-UP (efficacy and safety of mri-based thrombolysis in wake-up stroke: a randomized, doubleblind, placebo-controlled trial) by Thomalla, Götz et al.
  
 
 
 
 
Thomalla, G. et al. (2017) Stroke with unknown time of symptom onset: baseline 
clinical and magnetic resonance imaging data of the first thousand patients in WAKE-
UP (efficacy and safety of mri-based thrombolysis in wake-up stroke: a randomized, 
doubleblind, placebo-controlled trial). Stroke, 48(3), pp. 770-773. 
 
   
There may be differences between this version and the published version. You are 
advised to consult the publisher’s version if you wish to cite from it. 
 
 
 
http://eprints.gla.ac.uk/136969/ 
     
 
 
 
 
 
 
Deposited on: 15 March 2017 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
Stroke with unknown time of symptom onset – baseline clinical and 
MRI data of the first thousand patients in WAKE-UP 
 
Götz Thomalla, MD1, Florent Boutitie, PhD2, Jochen B. Fiebach, MD3, Claus Z. Simonsen, 
MD, PhD4, Norbert Nighoghossian, MD55, Salvador Pedraza, MD6, Robin Lemmens, MD7, 
Pascal Roy, MD2, Keith W. Muir, MD8, Martin Ebinger, MD3, 9, Ian Ford, PhD10, Bastian 
Cheng, MD1, Ivana Galinovic, MD3, Tae-Hee Cho, MD7, Josep Puig5, MD, Vincent Thijs11, 
MD, Matthias Endres, MD3, 9, Jens Fiehler, MD12, Christian Gerloff, MD1, on behalf of the 
WAKE-UP investigators 
 
1 Klinik und Poliklinik für Neurologie, Kopf- und Neurozentrum, Universitätsklinikum Hamburg-
Eppendorf, Hamburg, Germany 
2 Hospices Civils de Lyon, Service de Biostatistique, F-69003 Lyon, France; Université Lyon 1, F-
69100 Villeurbanne, France; CNRS, UMR 5558, Laboratoire de Biométrie et Biologie Evolutive, 
Equipe Biostatistique-Santé, F-69100 Villeurbanne, France 
3 Centrum für Schlaganfallforschung Berlin (CSB), Charité - Universitätsmedizin Berlin, Berlin, 
Germany 
4 Department of Neurology, Aarhus University Hospital, Aarhus, Denmark 
5 Department of Neurology, Hospices Civils de Lyon, Lyon, France 
6 Department of Radiology, Institut de Diagnostic per la Image (IDI), Hospital Dr Josep Trueta, Institut 
d’Investgació Biomèdica de Girona (IDIBGI), Girona, Spain 
7 Department of Neurology, University Hospitals Leuven, Leuven, Belgium 
8 Institute of Neuroscience & Psychology, University of Glasgow, Glasgow, UK 
9 Klinik und Hochschulambulanz für Neurologie, Charité-Universitätsmedizin Berlin, Berlin, Germany 
10 Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK 
11 Florey Institute of Neuroscience and Mental Health, Heidelberg, Victoria,  
12 Klinik und Poliklinik für Neuroradiologische Diagnostik und Intervention, Diagnostikzentrum, 
Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany 
 
G. Thomalla et al., Characteristics of unknown symptom onset stroke  Page 2 
 
 
Corresponding author: 
Götz Thomalla 
Kopf- und Neurozentrum, Klinik und Poliklinik für Neurologie 
Universitätsklinikum Hamburg-Eppendorf 
Martinistraße 52 
D-20246 Hamburg 
Germany 
E-mail: thomalla@uke.de 
telephone: +49-40-7410-50137 
fax: +49-40-42803-7410-56721 
 
 
Cover title 
Characteristics of unknown symptom onset stroke  
 
Word count  
Total:      2.393 
Abstract:     204 
Tables:     1 
Figures:      1 
References:     9 
 
Key words: Acute ischemic stroke, time window, wake-up, clinical trials, diffusion weighted 
imaging, fluid attenuated inversion recovery imaging, WAKE-UP 
G. Thomalla et al., Characteristics of unknown symptom onset stroke  Page 3 
 
 
Abstract 
Background and Purpose – We describe clinical and magnetic resonance imaging imaging 
characteristics of stroke patients with unknown time of symptom onset potentially eligible for 
thrombolysis from a large prospective cohort.  
Methods – We analysed baseline data from WAKE-UP, an investigator-initiated, randomised, 
placebo-controlled trial of MRI based thrombolysis in stroke patients with unknown time of 
symptom onset. MRI judgement included assessment of DWI-FLAIR-mismatch.  
Results – Of 1,005 patients included, DWI-FLAIR-mismatch was present in 479 patients 
(48.0%). Patients with daytime unwitnessed stroke (n=138, 13.7%) had a shorter delay 
between symptom recognition and hospital arrival (1.5 vs. 1.8 hours, p=0.002), a higher 
NIHSS on admission (8 vs. 6, p<0.001), and more often aphasia (72.5% vs. 34.0%, p<0.001) 
as compared to wake-up stroke patients. Frequency of DWI-FLAIR-mismatch was 
comparable between both groups (43.7% vs. 48.7%, p=0.30). 
Conclusions – Almost half of the patients with unknown time of symptom onset stroke 
otherwise eligible for thrombolysis had MRI findings making them likely to be within a time 
window for safe and effective thrombolysis. Patients with daytime onset unwitnessed stroke 
differ from wake-up stroke patients with regards to clinical characteristics but are comparable 
in terms of MRI characteristics of lesion age. 
Clinical Trial Registration – URL: http://www.clinicaltrials.gov. Unique identifier: 
NCT01525290; URL: https://www.clinicaltrialsregister.eu. Unique identifier: 2011-005906-32.
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Introduction 
In a large proportion of stroke patients information on the exact time of symptom onset is not 
available. This includes the large group of patients waking up with stroke symptoms, the so 
called “wake-up” stroke, representing around one in five (14-24%) of stroke patients in 
registries or epidemiological studies.1, 2 Information on time of symptom onset may also be 
unavailable in unwitnessed stroke at daytime in patients not capable of providing this 
information themselves. All these patients are currently excluded from reperfusion treatment 
based on the available evidence.3  
Magnetic resonance imaging (MRI) has been suggested to select patients with unknown time 
of symptom onset likely to benefit from acute reperfusion treatment using DWI-FLAIR-
mismatch as surrogate marker of lesion age.4 However, the proportion of patients qualifying 
for intravenous thrombolysis based on imaging criteria within a population of unknown 
symptom onset stroke patients otherwise considered eligible is not known. Furthermore, 
there are findings indicating that patients with wake-up stroke might differ from those with 
daytime unwitnessed stroke with regards to clinical and imaging characteristics that might 
affect acute treatment decisions.5  
We aimed at studying clinical and imaging characteristics of stroke patients with unknown 
time of symptom onset otherwise considered eligible for treatment with intravenous 
thrombolysis.  
 
Methods  
We analysed baseline data from WAKE-UP (Efficacy and safety of MRI-based thrombolysis 
in wake-up stroke: a randomised, double-blind, placebo-controlled trial), a trial enrolling acute 
stroke patients with unknown time of symptom onset (Clinicaltrials.gov identifier 
NCT01525290; EudraCT No.: 2011-005906-32).6 In this trial, patients are studied with MRI 
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including DWI and FLAIR, and the presence of a DWI-FLAIR mismatch4 represents the main 
imaging criterion for randomization to treatment with Alteplase or placebo. For the present 
analysis, only baseline information including demographic, clinical, and imaging data was 
considered. A database export was performed on 01 April 2016. The sample includes all 
patients enrolled in the trial, i.e. patients with eligibility verified who gave informed consent 
and were then subjected to screening with MRI. All patients with at least information on date 
and time of enrolment, informed consent, symptom onset, age and gender were included in 
the analysis. 
MRI judgement was made by local investigators according to image analysis standards 
provided together with the study protocol. Unwitnessed day-time stroke was compared to 
night-sleep wake-up stroke.  
For group comparison, Fisher’s exact test or Chi-square test were used for categorical 
variables, and Mann-Whitney-U test for continuous variables. SAS software, version 9·3 
(SAS Institute Inc., Cary, NC) was used for statistical analysis. 
 
Results 
Overall, 1,005 patients were included in the analysis. In the majority of patients, stroke 
symptoms were discovered in the morning hours between 06:00 and 10:00  (see figure). 
Clinical and imaging characteristics are presented in the table. Overall, 793 patients (81.3%) 
had a visible DWI lesion, while 72 (7.2%) had findings of intracranial haemorrhage. DWI-
FLAIR-mismatch was present in 479 patients (48.0%).  
Patients with daytime unwitnessed stroke had a shorter delay between symptom recognition 
and arrival at the hospital (1.5 vs. 1.8 h, p=0.002), a higher NIHSS on admission (8 vs. 6, 
p<0.001), and more frequently aphasia (72.5% vs. 34.0%, p<0.001). Medical history and 
presence of vascular risk factors were similar between groups. Groups were also 
comparable as to baseline imaging findings including the proportion of patients presenting 
with DWI-FLAIR-mismatch (43.7% vs. 48.7%, p=0.30). 
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Discussion 
In this large prospective sample consisting of the first 1,005 patients enrolled in the 
multicentre multinational randomized controlled WAKE-UP trial, DWI-FLAIR-mismatch was 
observed in virtually half of the patients (48.0%). This confirms the notion that a relevant 
proportion of patients with unknown time of symptom onset has an MRI signature indicative 
of stroke lesions within the first 4.5 hours of symptom onset. The number is comparable to 
the 43.7% DWI-FLAIR-mismatch reported in a previous small case series of stroke with 
unknown time of symptom onset.7 In another recently published case series, DWI-FLAIR-
mismatch was present in only 35.1% of daytime unwitnessed stroke and 21.9% of patients 
with wake-up stroke.5 Smaller numbers may result from a longer delay between symptom 
recognition to hospital arrival as compared to our sample.  
Comparing patients waking up from night-sleep to those with daytime unwitnessed stroke 
revealed some differences. Patients with unknown time of symptom onset at daytime had 
more severe neurological symptoms reflected by a higher NIHSS on admission, a higher rate 
of aphasia, and a trend towards a higher rate of disturbed level of consciousness. These 
results are in line with a recently published retrospective analysis reporting higher mean 
NIHSS values for and higher rates of aphasia in patients with day-time onset unwitnessed 
stroke as compared to wake-up stroke.5 As aphasia and disturbed level of consciousness 
represent common reasons for the inability of patients with daytime onset stroke to report the 
time of symptom onset, these findings might at least in part be considered as a bias resulting 
from the definition of unwitnessed stroke at daytime. On the other hand, there are hints 
towards pathophysiological differences between strokes occurring at night and those at 
daytime which may contribute to differences in risk profile, stroke etiology, and symptom 
severity between groups. A higher risk of newly diagnosed atrial fibrillation was observed in 
wake-up stroke,8 that might relate to the well-known circadian variation of occurrence of atrial 
fibrillation with most frequent occurrence in the early morning hours.9  
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To summarise, in this large prospective cohort of stroke patients with unknown time of 
symptom onset otherwise considered potential candidates for thrombolysis, almost half of the 
patients showed a DWI-FLAIR-mismatch, rendering them likely to be within a time window 
for effective reperfusion treatment. We found no difference in the presence of DWI-FLAIR-
mismatch between patients with wake-up stroke and those with daytime unwitnessed stroke, 
but the analysis was not adequately powered to detect if the observed small absolute 
difference was statistically significant. When considering reperfusion treatment in patients 
with unknown time of symptom onset, these considerations should not be restricted to wake-
up strokes but also include daytime onset unwitnessed stroke. 
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Tables 
Table: Clinical characteristics and imaging findings 
 All 
(n=1005) 
Nightsleep 
wake-up 
stroke 
(n=867) 
Daytime 
unwitnessed 
stroke 
(n=138) 
Group 
comparison  
p-value 
Age [years], median (IQR) 68.0 (58.0-
75.0) 
68.0 (58.0-
74.0) 
68.0 (58.0-
74.0) 
0.90 
Gender = female, n (%) 390 (38.8) 328 (37.8) 62 (44.9) 0.13 
Delay between last seen well and 
symptom recognition [h], median 
(IQR) 
7.7 (5.5-9.5) 7.5 (5.8-9.3) 8.0 (4.0-12.7) 0.33 
Delay between symptom 
recognition and arrival at hospital 
[h], median (IQR) 
1.8 (1.2-2.5) 1.8 (1.2-2.6) 1.5 (1.0-2.1) 0.002 
Medical history / risk factors * 
Arterial hypertension, n (%) 
Diabetes mellitus, n (%) 
Hypercholesterolemia, n (%) 
Atrial fibrillation, n (%) 
Ischemic stroke, n (%) 
Transient ischemic attack, n (%) 
 
472/989 (48.1) 
159/967 (16.2) 
275/935 (28.1) 
74/959 (7.6) 
120/973 (12.3) 
46/967(4.7) 
 
410/837 (48.6) 
134/833 (15.9) 
235/819 (27.9) 
65/829 (7.7) 
97/837 (11.5) 
42/835 (5.0) 
 
62/132 (45.3) 
25/134 (18.3) 
40/126 (29.2) 
9/130 (6.6) 
23/135 (16.8) 
4/132 (2.9) 
 
0.71 
0.45 
0.53 
0.86 
0.09 
0.39 
NIHSS on admission, median 
(IQR) 
6 (4-11) 6 (3-10) 8 (5-14) <0.001 
Aphasia, n (%) 392 (39.3) 292 (34.0) 100 (72.5) <0.001 
Disturbed level of consciousness 
(NIHSS LOC item >1), n (%) 
83 (8.3) 66 (7.7) 17 (12.3) 0.10 
MR imaging findings 
Images of sufficient quality, n (%) 
Intracranial haemorrhage†, n (%) 
Acute DWI lesion, n (%) 
DWI-FLAIR-mismatch present, n 
(%) 
 
960 (98.1) 
72 (7.2) 
793 (81.3) 
479 (48.0) 
 
 
62 (7.4) 
689 (83.4) 
429 (48.7) 
 
 
10 (7.6) 
104 (79.4) 
59 (43.7) 
 
 
0.86 
0.26 
0.31 
* Percentage calculated with reference to number of patients with information available;  
† intracerebral haemorrhage, subarachnoid haemorrhage, intraventricular haemorrhage, hemorrhagic 
transformation;  
IQR = interquartile range; NIHSS = National Institutes of Stroke Scale; LOC = level of consciousness; 
DWI = diffusion weighted imaging; FLAIR = fluid attenuated inversion recovery 
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Figure legends 
Figure: Timing of Symptom Discovery among Patients with Unwitnessed Onset  
The figure shows the distribution of the time of day at which symptoms were discovered for 
all patients (available for n=1.003, missing for n=2). 
 
